MCM
HRTX icon

MAI Capital Management’s Heron Therapeutics HRTX Stock Holding History

MAI Capital Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-695
Closed -$557 – 3255
2026
Q1 		$557 Buy
+695
New +$805 ﹤0.01% 4377

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

MAI Capital Management's HRTX Position: Q2 2026 in Review

MAI Capital Management sold out of Heron Therapeutics (HRTX) in Q2 2026, closing a stake of 695 shares — an estimated $557 sold.

MAI Capital Management first reported a position in HRTX in Q1 2026 and held it in 1 quarter. The position peaked at $557 in Q1 2026. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • MAI Capital Management reported no remaining Heron Therapeutics position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 695 Heron Therapeutics shares in Q2 2026, an estimated $557.
  • MAI Capital Management first reported a position in Heron Therapeutics in Q1 2026 and held it in 1 quarter.
  • MAI Capital Management's Heron Therapeutics position peaked at $557 in Q1 2026.
  • 163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.